| Variables . | Study population . | Total HIV-2 cohort . |
|---|---|---|
| No. of subjects | 73 | 236 |
| Gender | ||
| male | 49 (67%) | 155 (66%) |
| female | 24 (33%) | 77 (33%) |
| unknown | 0 | 4 (2%) |
| Median age, years (range) | 39 (2–78) | 40 (2–84) |
| Risk group | ||
| heterosexual contact | 56 (77%) | 145 (61%) |
| men who have sex with men | 5 (7%) | 12 (5%) |
| intravenous drug users | 2 (3%) | 3 (1%) |
| vertical | 1 (1%) | 1 (0.5%) |
| transfusion | 0 | 1 (0.5%) |
| unknown | 9 (12%) | 74 (31%) |
| Country of origin | ||
| native Spaniards | 15 (21%) | 40 (17%) |
| sub-Saharan Africa | 49 (67%) | 179 (76%) |
| Portugal | 5 (7%) | 6 (3%) |
| India | 0 | 1 (0.5%) |
| France | 0 | 1 (0.5%) |
| Latin America | 1 (1%) | 2 (1%) |
| unknown | 3 (4%) | 7 (3%) |
| Co-infection with HIV-1 | 6 (8%) | 24 (10%) |
| HIV-2 group | ||
| A | 65 | 65 |
| B | 8 | 8 |
| unknown | 0 | 163 |
| Variables . | Study population . | Total HIV-2 cohort . |
|---|---|---|
| No. of subjects | 73 | 236 |
| Gender | ||
| male | 49 (67%) | 155 (66%) |
| female | 24 (33%) | 77 (33%) |
| unknown | 0 | 4 (2%) |
| Median age, years (range) | 39 (2–78) | 40 (2–84) |
| Risk group | ||
| heterosexual contact | 56 (77%) | 145 (61%) |
| men who have sex with men | 5 (7%) | 12 (5%) |
| intravenous drug users | 2 (3%) | 3 (1%) |
| vertical | 1 (1%) | 1 (0.5%) |
| transfusion | 0 | 1 (0.5%) |
| unknown | 9 (12%) | 74 (31%) |
| Country of origin | ||
| native Spaniards | 15 (21%) | 40 (17%) |
| sub-Saharan Africa | 49 (67%) | 179 (76%) |
| Portugal | 5 (7%) | 6 (3%) |
| India | 0 | 1 (0.5%) |
| France | 0 | 1 (0.5%) |
| Latin America | 1 (1%) | 2 (1%) |
| unknown | 3 (4%) | 7 (3%) |
| Co-infection with HIV-1 | 6 (8%) | 24 (10%) |
| HIV-2 group | ||
| A | 65 | 65 |
| B | 8 | 8 |
| unknown | 0 | 163 |
| Variables . | Study population . | Total HIV-2 cohort . |
|---|---|---|
| No. of subjects | 73 | 236 |
| Gender | ||
| male | 49 (67%) | 155 (66%) |
| female | 24 (33%) | 77 (33%) |
| unknown | 0 | 4 (2%) |
| Median age, years (range) | 39 (2–78) | 40 (2–84) |
| Risk group | ||
| heterosexual contact | 56 (77%) | 145 (61%) |
| men who have sex with men | 5 (7%) | 12 (5%) |
| intravenous drug users | 2 (3%) | 3 (1%) |
| vertical | 1 (1%) | 1 (0.5%) |
| transfusion | 0 | 1 (0.5%) |
| unknown | 9 (12%) | 74 (31%) |
| Country of origin | ||
| native Spaniards | 15 (21%) | 40 (17%) |
| sub-Saharan Africa | 49 (67%) | 179 (76%) |
| Portugal | 5 (7%) | 6 (3%) |
| India | 0 | 1 (0.5%) |
| France | 0 | 1 (0.5%) |
| Latin America | 1 (1%) | 2 (1%) |
| unknown | 3 (4%) | 7 (3%) |
| Co-infection with HIV-1 | 6 (8%) | 24 (10%) |
| HIV-2 group | ||
| A | 65 | 65 |
| B | 8 | 8 |
| unknown | 0 | 163 |
| Variables . | Study population . | Total HIV-2 cohort . |
|---|---|---|
| No. of subjects | 73 | 236 |
| Gender | ||
| male | 49 (67%) | 155 (66%) |
| female | 24 (33%) | 77 (33%) |
| unknown | 0 | 4 (2%) |
| Median age, years (range) | 39 (2–78) | 40 (2–84) |
| Risk group | ||
| heterosexual contact | 56 (77%) | 145 (61%) |
| men who have sex with men | 5 (7%) | 12 (5%) |
| intravenous drug users | 2 (3%) | 3 (1%) |
| vertical | 1 (1%) | 1 (0.5%) |
| transfusion | 0 | 1 (0.5%) |
| unknown | 9 (12%) | 74 (31%) |
| Country of origin | ||
| native Spaniards | 15 (21%) | 40 (17%) |
| sub-Saharan Africa | 49 (67%) | 179 (76%) |
| Portugal | 5 (7%) | 6 (3%) |
| India | 0 | 1 (0.5%) |
| France | 0 | 1 (0.5%) |
| Latin America | 1 (1%) | 2 (1%) |
| unknown | 3 (4%) | 7 (3%) |
| Co-infection with HIV-1 | 6 (8%) | 24 (10%) |
| HIV-2 group | ||
| A | 65 | 65 |
| B | 8 | 8 |
| unknown | 0 | 163 |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
